1. Home
  2. AMBO vs KPRX Comparison

AMBO vs KPRX Comparison

Compare AMBO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambow Education Holding Ltd.

AMBO

Ambow Education Holding Ltd.

HOLD

Current Price

$2.33

Market Cap

7.2M

Sector

Real Estate

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.54

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBO
KPRX
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
8.0M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
AMBO
KPRX
Price
$2.33
$2.54
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
8.1K
617.6K
Earning Date
08-05-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
337.04
N/A
EPS
0.02
N/A
Revenue
$9,469,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$98.59
N/A
Revenue Growth
0.82
N/A
52 Week Low
$1.47
$1.76
52 Week High
$6.75
$4.18

Technical Indicators

Market Signals
Indicator
AMBO
KPRX
Relative Strength Index (RSI) 55.28 62.75
Support Level $1.97 $1.90
Resistance Level $2.43 $2.94
Average True Range (ATR) 0.27 0.21
MACD 0.03 0.05
Stochastic Oscillator 64.32 65.79

Price Performance

Historical Comparison
AMBO
KPRX

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: